0000899243-17-003618.txt : 20170210
0000899243-17-003618.hdr.sgml : 20170210
20170210192300
ACCESSION NUMBER: 0000899243-17-003618
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161024
FILED AS OF DATE: 20170210
DATE AS OF CHANGE: 20170210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: AESCHENVORSTADT 36
CITY: BASEL
STATE: V8
ZIP: 4051
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: AESCHENVORSTADT 36
CITY: BASEL
STATE: V8
ZIP: 4051
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EMSTER KURT VON
CENTRAL INDEX KEY: 0001252524
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 17595289
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD
STREET 2: SUITE 350
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-10-24
0
0001674416
CRISPR Therapeutics AG
CRSP
0001252524
EMSTER KURT VON
C/O CRISPR THERAPEUTICS, INC.
200 SIDNEY STREET
CAMBRIDGE
MA
02139
1
0
0
0
Common Shares
2016-10-24
4
C
0
2354050
0.00
A
2354050
I
See Footnote
Common Shares
2016-10-24
4
C
0
191764
0.00
A
2545814
I
See Footnote
Common Shares
2016-10-24
4
P
0
56000
14.00
A
2601814
I
See Footnote
Series A-3 Preferred Shares
0.00
2016-10-24
4
C
0
2354050
0.00
D
Common Shares
2354050
0
I
See Footnote
Series B Preferred Shares
0.00
2016-10-24
4
C
0
191764
0.00
D
Common Shares
191764
0
I
See Footnote
These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date.
These shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
/s/ Kurt von Emster
2017-02-10